TCL Archive Klausner To Revamp NCI Budget Process To Make Categories Mean What They Say December 8, 1995
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Cancer research poised for a “platinum age” as a “golden age” ends, NCI director tells AACR annual meeting. April 29, 2005
TCL Archive Institute Of Medicine Report Says Insurers Should Pay Patient Care Costs In Clinical Trials February 24, 1989
